An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
NCT ID: NCT05827887
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2023-06-25
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Urogepant (Ubrelvy) and Atogepant (Qulipta) are approved drugs for treatment of migraine in adults in the US. Approximately 200 adult participants who are prescribed Ubrogepant or atogepant by their doctors will be enrolled in this study in Israel.
Participants will receive ubrogepant oral tablets or atogepant oral tablets as prescribed by their physician. Participants will be followed for 90 days.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ubrogepant
Participants will receive ubrogepant as prescribed by their physician in routine clinical practice.
No interventions assigned to this group
Atogepant
Participants will receive atogepant as prescribed by their physician in routine clinical practice.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients should be naive to the designated treatment
* Ability to fill an e-diary app
Exclusion Criteria
* Patients participating in a concurrent clinical interventional study or within the last 30 days
* Patients who were previously treated with rimegepant will be excluded from the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Edith Wolfson Medical Center /ID# 269740
Holon, Central District, Israel
Maccabi Healthcare Services /ID# 254171
Kfar Saba, Central District, Israel
Meir Medical Center /ID# 254170
Kfar Saba, Central District, Israel
Shaare Zedek Medical Center /ID# 254169
Jerusalem, Jerusalem, Israel
Hadassah Medical Center-Hebrew University /ID# 257352
Jerusalem, Jerusalem, Israel
ZIV Medical Center /ID# 257360
Safed, Northern District, Israel
Assuta Ashdod Medical Center /ID# 260020
Ashdod, Southern District, Israel
Soroka University Medical Center /ID# 254551
Beersheba, Southern District, Israel
The Chaim Sheba Medical Center /ID# 254550
Ramat Gan, Tel Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 263089
Tel Aviv, Tel Aviv, Israel
Clalit HMO /ID# 257364
Gani Tikva, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P24-078
Identifier Type: -
Identifier Source: org_study_id